Abstract:FoxM1 is known to play important role in the development and progression of many malignancies including pancreatic cancer. Studies have shown that the acquisition of epithelial-to-mesenchymal transition (EMT) phenotype and induction of cancer stem cell (CSC) or cancer stem-like cell phenotypes are highly inter-related, and contributes to drug resistance, tumor recurrence, and metastasis. The molecular mechanism(s) by which FoxM1 contributes to the acquisition of EMT phenotype and induction of CSC self-renewal capacity is poorly understood. Therefore, we established FoxM1 over-expressing pancreatic cancer (AsPC-1) cells, which showed increased cell growth, clonogenicity, and cell migration. Moreover, over-expression of FoxM1 led to the acquisition of EMT phenotype by activation of mesenchymal cell markers, ZEB1, ZEB2, Snail2, E-cadherin, and vimentin, which is consistent with increased sphere-forming (pancreatospheres) capacity and expression of CSC surface markers (CD44 and EpCAM). We also found that over-expression of FoxM1 led to decreased expression of miRNAs (let-7a, let-7b, let-7c, miR-200b, and miR-200c); however, re-expression of miR-200b inhibited the expression of ZEB1, ZEB2, vimentin as well as FoxM1, and induced the expression of E-cadherin, leading to the reversal of EMT phenotype. Finally, we found that genistein, a natural chemo-preventive agent, inhibited cell growth, clonogenicity, cell migration and invasion, EMT phenotype, and formation of pancreatospheres consistent with reduced expression of CD44 and EpCAM. These results suggest, for the first time, that FoxM1 over-expression is responsible for the acquisition of EMT and CSC phenotype, which is in part mediated through the regulation of miR-200b and these processes, could be easily attenuated by genistein.

Supplementary Figure Legend from FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis Via Upregulation of Expression of the Urokinase Plasminogen Activator System

Supplementary Figure 1 from FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis Via Upregulation of Expression of the Urokinase Plasminogen Activator System

Supplementary Materials and Methods from FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis Via Upregulation of Expression of the Urokinase Plasminogen Activator System

Over‐expression of FoxM1 Leads to Epithelial–mesenchymal Transition and Cancer Stem Cell Phenotype in Pancreatic Cancer Cells

Supplementary Figure 1 from FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression Via Transactivation of LDHA Expression

Supplementary Figures 1 - 7 from Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer

Supplementary Figure 4 from FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression

Supplementary Methods from Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer

Overexpression of FoxP 1 is a novel biomarker of malignant human pancreatic cancer

Supplementary Figure Legends 1-2 from Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment

FOXM1 and Its Oncogenic Signaling in Pancreatic Cancer Pathogenesis.

Supplementary Figures 1-14, Tables 1-3 from Forkhead Transcription Factor Foxq1 Promotes Epithelial–Mesenchymal Transition and Breast Cancer Metastasis

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

SUPPLEMENTARY figure 5 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Supplementary Figure Legends from PDLIM1 Stabilizes the E-Cadherin/β-Catenin Complex to Prevent Epithelial–Mesenchymal Transition and Metastatic Potential of Colorectal Cancer Cells

Supplementary Figure from <i>FOXM1</i> Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer

SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Supplementary Figure Legends 1-2 from Definition of Micrornas That Repress Expression of the Tumor Suppressor Gene <i>foxo1</i> in Endometrial Cancer

FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes

Supplementary Figure 1 from FoxM1B Transcriptionally Regulates Vascular Endothelial Growth Factor Expression and Promotes the Angiogenesis and Growth of Glioma Cells

Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis